Plain-English translation of NCT03649880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging technique called FMISO PET scanning to help doctors see which parts of brain tumors are not getting enough oxygen. The study combines this new scan with standard MRI images to create a clearer picture of your tumor. Researchers hope this information will help them tell whether a tumor is responding to treatment or growing back.
Currently, doctors sometimes struggle to tell the difference between a tumor that is shrinking in response to immunotherapy and one that is actually growing back. This new imaging approach could give doctors a clearer way to monitor your tumor and make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the study medication, then spend about 2 hours undergoing imaging scans (PET and MRI or CT) to see how the medication behaves in your tumor. You'll return within a week for a repeat scan to make sure the results are consistent. After these initial scans, you may have up to 2 more imaging sessions spaced at least 4 weeks apart. You'll be followed for up to 5 years to track your health and tumor response.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States